Introduction
The incidence of renal cell carcinoma (RCC) has been increasing since 1980s in western countries as well as Japan and is now the third most common malignancy of the urinary tract following prostate and bladder cancers [1] . Although early detection and treatment are considered to be the most effective methods to improve the outcome of patients with any cancer, RCC patients often do not manifest clinical symptoms and receive medical attention until their tumors progress to advanced stages [2] [3] [4] . Recently, ultrasound and CT scan can detect smaller renal tumors. However, we do need an effective plasma biomarker for differentiating the malignant from the benign when a patient was found with a small renal mass, which cannot be easily judged from ultrasound or CT scan [5] . Therefore, it is necessary to identify the tumor marker better than neither ultrasound test nor CT scan in diagnosing small renal mass. If a sensitive but non-invasive blood assay that can detect early-stage RCC were available, it would greatly improve the curative rate of RCC.
Shotgun proteomics is an established technique in which whole proteins are enzymatically digested into a large array of small peptide fragments followed by direct analysis by liquid chromatography and mass spectrometry (LC-MS). We previously developed software named 2DICAL that can provide a quantitative dimension to shotgun proteomics [6] . 2DICAL can accurately align different LC-MS data and compare the protein content of a theoretically unlimited number of samples without isotope labeling [7] . 2DICAL is highly advantageous methods in clinical studies that require the comparison of a statistically sufficient number of patient samples [8] . Using 2DICAL, we were able to identify diagnostic biomarkers for endometrial and pancreatic cancers [7, 8] and predictive biomarkers for hematologic toxicities and therapeutic efficacy of gemcitabine treatment to patients with advanced pancreatic cancer [9] .
In this study we compared the plasma proteome between RCC patients and healthy controls using 2DI-CAL with the aim to identify a new diagnostic biomarker that can be used for a blood test. RCC consists of clear cell (75%), papillary (10%), chromophobe (5%) and other subtypes [10] , and we first focused on clear cell carcinoma, the most common subtype of RCC. We discovered a significant increase of circulating plasma FN1 in patients with RCC and confirmed its significance in a larger patient cohort using a newly established measurement system.
Materials and methods

Plasma samples
Plasma samples were prospectively collected from RCC patients, prostate cancer patients and healthy volunteers at the Department of Urology, Kyushu University Hospital (Fukuoka, Japan) between October 2000 and January 2008. To exclude sampling bias, all the patients' whole blood (7 ml) was collected in the same tube (EDTA-2Na tube, Venoject II, Terumo, Japan) before the surgery or first treatment. These blood samples were stored in 4
• C for 1 hour and plasma was separated after centrifugation, aliquoted into 1 ml samples in 1.5 ml eppendorf tubes, and stored at −80
• C. The control samples were collected and stored under the same condition. All the samples had the only one cycle of freeze-and-thaw. As we excluded the non-clear cell subtype and benign kidney tumors, the plasma from 77 histopathologically proven clear cell cancer patients were used for the analysis. Control plasma samples were randomly selected from 20 patients with prostate cancer and 130 healthy individuals after adjusting the age and gender. The clinical stage of each patient was classified according to the 7th edition UICC TNM classification [11] . Twenty RCC patients (excluding those in stage IV) were selected for analysis using 2DICAL in an effort to detect early stage biomarkers (Table 1) .
Ethics
All individuals provided written informed consent authorizing the collection and use of their samples for research purposes. The protocol was reviewed and approved by the institutional ethics committee boards of the National Cancer Center Research Institute (Tokyo, Japan) and the Kyushu University (Fukuoka, Japan).
LC-MS
The 20 most abundant plasma proteins including albumin and immunoglobulin were removed using ProtPrep 20 Plasma Immunodepletion Kit (Sigma-Aldrich, St. Louis, MO) following the manufacturer's instructions. The depleted plasma samples were then digested with trypsin (Promega, Madison, WI) overnight at 37
• C. The resulting peptides were randomized and measured in triplicate by LC-MS. LC separation in a linear gradient of 0 to 80% acetonitrile in 0.1% formic acid at a speed of 200 nL/minute for 60 minutes was conducted using a splitless nano-flow HPLC system (Hitachi High-technologies, Tokyo, Japan). MS data were acquired every second for 60 minutes by an electrospray ionization mass spectrometer (Q-TOF Ultima; Waters, Milford, MC) directly linked to an LC in the range of 250-1600 m/z. MS peaks were detected, normalized, and quantified using the in-house 2DICAL software package as described previously [7] . A serial ID number was applied to each of the MS peaks detected (ID 1 to 23,407) [9] . The stability of LC-MS was monitored by calculating the correlation coefficient (CC) and coefficient of variance (CV) values among triplicate measurements.
Protein identification by tandem mass spectrometry (MS/MS)
Peak lists were generated using the Mass Navigator software package (version 1.2) (Mitsui Knowledge Industry, Tokyo, Japan) and searched against the SwissProt database (SwissProt 57.6.fast) using the Mascot software package (version 2.2.06) (Matrix Science, London, UK). The search parameters used were as follows: A database of human proteins was selected. Table 1 Clinicopathological characteristics of individuals examined in this study Trypsin was designated as the enzyme, and up to one missed cleavage was allowed. Mass tolerances for precursor and fragment ions were ± 0.2 Da and ± 0.8 Da, respectively. The score threshold was set to the value over 20 for peptide search. If a peptide matched to multiple proteins, the protein name with the highest Mascot score was selected.
Western blot analysis
Plasma samples were fractionated with SDS-PAGE and electroblotted onto a polyvinylidene difluoride membrane (Millipore, Billerica, MA), as described previously [9, 12] . Primary antibodies used were mouse monoclonal anti-FN1 antibody (R&D Systems, Minneapolis, MN) and mouse monoclonal antibody against human complement C3b-α (PROGEN, Heidelberg, Germany) [8] . The membrane was then incubated with the primary antibody and subsequently with the relevant horseradish peroxidase-conjugated anti-mouse IgG as described previously. Blots were developed using an enhanced chemiluminescence (ECL plus) detection system (GE Healthcare, Buckinghamshire, UK).
AlphaLISA
An assay for measuring soluble FN1 was constructed using the AlphaLISA system (PerkinElmer,MA) which is a bead-bead nonradioactive technology. In brief, when a biological interaction brings the beads into close proximity, a cascade of chemical reactions is induced resulting in a greatly amplified signal, then a photosensitizer present in the beads converts ambient oxygen to a more excited singlet state upon laser excitation. Biotinylated rabbit polyclonal anti-FN1 antibody and mouse polyclonal anti-FN1 antibody were purchased from Abcam (Cambridge, UK). The AlphaLISA procedure was carried out according to the protocol provided by the manufacturer.
Statistical methods
The Mann-Whitney U-test was employed for statistical analysis of the correlation between RCC patients and controls as well as the plasma values of FN1 and clinicopathological parameters. Welch's t-test was employed for 2DICAL analysis. Kaplan-Meier analysis was used to examine the correlation of the plasma value of FN1, cancer-specific survival and overall survival. The area under the curve (AUC) of the receiver operating characteristic (ROC) was calculated to evaluate its diagnostic significance.
Results
Identification of plasma proteins significantly increased in RCC patients
Plasma proteins of 20 patients with RCC and 20 healthy individuals were digested by trypsin, and 
-test).
Thirty six peaks were increased and 23 peaks were decreased in RCC patients and the statistical significance was confirmed by calculating the false discovery rate (FDR) values [13] (data not shown). Figure 1a shows a representative 2-dimensional view in which all the ∼23,000 MS peaks were displayed with the m/z along the X axis and the RT of LC along the Y axis and the 59 MS peaks are highlighted in red. Figure 1b shows a representative MS peak that increased in the plasma of RCC patients.
Protein identification by MS/MS
Fifty seven MS/MS spectra acquired from the 59 MS peaks matched to 21 peptide sequences deposited in the human protein database (Table 2 ). Remarkably, 16 of the 21 peptides were found to be derived from the amino acid sequence of FN1 gene product (Supportive information Figs S1 and S2) . The identification and differential expression of FN1 protein were confirmed by immunoblotting (Fig. 1c) .
Verification by AlphaLISA
To validate the increased level of plasma FN1, we constructed a new assay that can quantify the amount of FN1. The AlphaLISA showed high reproducibility with a median CV value of 0.08 among triplicates and linearity in the range of 50-800 μg/ml.
The plasma concentration of FN1 was measured in 77 RCC patients, 20 prostate cancer (PCa) patients, and 130 healthy individuals by AlphaLISA. There was a significant difference between RCC patients (405 ± 153 μg/ml) and healthy individuals (294 ± 102 μg/ml) with a p-value of 1.8 × 10 −7 (Mann-Whitney U test) (Fig. 2a) . The plasma concentration of FN1 was not elevated in PCa patients (306 ± 81 μg/ml). The AUC value of ROC for plasma FN1 concentration of RCC patients to healthy individuals was calculated to be 0.71 for all stages, stage I and II and stage III and IV (Fig. 2b) . The optimum diagnostic cut-off point of FN1 was identified at 377 μg/ml by the AUC curve. At this point, sensitivity, specificity, PPV and NPV were 53%, 82%, 64% and 75% respectively. And the fibronectin concentration in each clinical stage was shown in Fig. 2c. 
Correlation of plasma concentration of FN1 and clinicopathological parameters
The statistical analyses were performed to detect the correlation of plasma concentration of FN1 and clinical stage (Fig. 2c) , but there were no significant differences. Also, there were no significant correlations between concentration of FN1 and the other clinicopathological parameters, such as tumor size, tumor grade and vascular involvement (data not shown). Furthermore, Kaplan-Meier analysis, used to analyze the correlation Table 2 Summary of protein identification by tandem mass spectrometry (a) (b) (c) of serum value of FN1, cancer-specific survival and overall survival, failed to prove any statistical significant differences with a median follow up of 47.6 months after surgery (data not shown).
Discussion
FN1 is a high-molecular-weight extracellular matrix protein that plays an important role in cellular attachment and cell spread [14, 15] . FN1 can be soluble or insoluble, is produced by hepatocytes and various cell types and is bound to integrins [16] . Altered expression of FN1 is known to change the morphology of several tumor cell lines [17] . In several studies of different RCC cell lines, FN1 was shown to be secreted into the culture medium and suggested to influence the movement and invasion of these cells [18] [19] [20] . Another study showed FN1 plasma levels signif-icantly elevated in localized and metastatic RCC patients compared to a control group [21] . According to "THE HUMAN PROTEIN ATLAS" (http://www. proteinatlas.org/ENSG00000115414), FN1 is expressed in extracellular matrix and stromal cell. FN1 is expressed weakly in normal kidney and relatively higher expressed in kidney cancer. It could be considerable that higher plasma levels of FN1 is secreted from these extracellular matrix and stromal cell in kidney cancer. A recent study suggested that FN1 mRNA expression was higher in RCC compared to normal renal tissue and correlated with advanced disease, suggesting that FN1 mRNA expression might serve as a marker for RCC aggressiveness [22] . Although the researchers failed to measure the plasma concentration of FN1, this study supports the results described herein obtained by proteome based screening.
The results of plasma FN1 from 2DICAL analysis were validated in a hundreds-scale cohort using a different methodology. AlphaLISA confirmed that the plasma level of FN1 was up-regulated in the early stage of RCC, which suggested that the FN1 plasma levels might be a tool for screening and diagnosis of RCC. However, there a limitation to introduce FN1 for screening of RCC, because plasma concentrations between patients and controls were overlapped extensively, and FN1 was not examined in benign renal tumors.
RCC comprises five histologically distinct subtypes classified by morphologic and pathologic features including clear cell (75%), papillary (10-15%), chromophobe (5-10%), collecting duct, and unclassified subtypes. We have previously reported that each RCC subtype has a totally different genetic profile by whole genome SNP array [10] . Therefore, each subtype should have a specific biomarker. In this study, we focused on clear cell RCC because it is the most abundant subtype of RCC and hence should be a first target of screening. Our comprehensive study of proteomics led to the possibility that monitoring the level of plasma FN1 could be clinically useful for the screening and diagnosis of RCC patients. The most of the patients we analyze were clinical stage I (56 cases / total 77 cases), and they had no symptoms such as febrile and showed normal range of C-reactive protein. Therefore, we believe that FN1 was not derived from acute phase reaction. Reports of the elevation of the plasma level of FN1 in RCC exist in the literature [21] , but its clinical usage has not yet been described. One of the reasons may be the lack of applicable clinical test such as ELISA for FN1. The assessment of plasma FN1 levels must be determined for a large scale clinical cohort, but the construction of an easy clinical test such as ELISA will be needed for its completion.
